These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 35353846)

  • 1. Communication about vaccine efficacy and COVID-19 vaccine choice: Evidence from a survey experiment in the United States.
    Kreps S; Kriner DL
    PLoS One; 2022; 17(3):e0265011. PubMed ID: 35353846
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative Effectiveness of Moderna, Pfizer-BioNTech, and Janssen (Johnson & Johnson) Vaccines in Preventing COVID-19 Hospitalizations Among Adults Without Immunocompromising Conditions - United States, March-August 2021.
    Self WH; Tenforde MW; Rhoads JP; Gaglani M; Ginde AA; Douin DJ; Olson SM; Talbot HK; Casey JD; Mohr NM; Zepeski A; McNeal T; Ghamande S; Gibbs KW; Files DC; Hager DN; Shehu A; Prekker ME; Erickson HL; Gong MN; Mohamed A; Henning DJ; Steingrub JS; Peltan ID; Brown SM; Martin ET; Monto AS; Khan A; Hough CL; Busse LW; Ten Lohuis CC; Duggal A; Wilson JG; Gordon AJ; Qadir N; Chang SY; Mallow C; Rivas C; Babcock HM; Kwon JH; Exline MC; Halasa N; Chappell JD; Lauring AS; Grijalva CG; Rice TW; Jones ID; Stubblefield WB; Baughman A; Womack KN; Lindsell CJ; Hart KW; Zhu Y; Mills L; Lester SN; Stumpf MM; Naioti EA; Kobayashi M; Verani JR; Thornburg NJ; Patel MM;
    MMWR Morb Mortal Wkly Rep; 2021 Sep; 70(38):1337-1343. PubMed ID: 34555004
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of COVID-19 Vaccines After Reports of Adverse Events Among Adult Recipients of Janssen (Johnson & Johnson) and mRNA COVID-19 Vaccines (Pfizer-BioNTech and Moderna): Update from the Advisory Committee on Immunization Practices - United States, July 2021.
    Rosenblum HG; Hadler SC; Moulia D; Shimabukuro TT; Su JR; Tepper NK; Ess KC; Woo EJ; Mba-Jonas A; Alimchandani M; Nair N; Klein NP; Hanson KE; Markowitz LE; Wharton M; McNally VV; Romero JR; Talbot HK; Lee GM; Daley MF; Mbaeyi SA; Oliver SE
    MMWR Morb Mortal Wkly Rep; 2021 Aug; 70(32):1094-1099. PubMed ID: 34383735
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of framing and communicating COVID-19 vaccine side-effect risks on vaccine intentions for adults in the UK and the USA: A structured summary of a study protocol for a randomized controlled trial.
    Sudharsanan N; Favaretti C; Hachaturyan V; Bärnighausen T; Vandormael A
    Trials; 2021 Sep; 22(1):592. PubMed ID: 34488843
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness of Homologous and Heterologous COVID-19 Booster Doses Following 1 Ad.26.COV2.S (Janssen [Johnson & Johnson]) Vaccine Dose Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults - VISION Network, 10 States, December 2021-March 2022.
    Natarajan K; Prasad N; Dascomb K; Irving SA; Yang DH; Gaglani M; Klein NP; DeSilva MB; Ong TC; Grannis SJ; Stenehjem E; Link-Gelles R; Rowley EA; Naleway AL; Han J; Raiyani C; Benitez GV; Rao S; Lewis N; Fadel WF; Grisel N; Griggs EP; Dunne MM; Stockwell MS; Mamawala M; McEvoy C; Barron MA; Goddard K; Valvi NR; Arndorfer J; Patel P; Mitchell PK; Smith M; Kharbanda AB; Fireman B; Embi PJ; Dickerson M; Davis JM; Zerbo O; Dalton AF; Wondimu MH; Azziz-Baumgartner E; Bozio CH; Reynolds S; Ferdinands J; Williams J; Schrag SJ; Verani JR; Ball S; Thompson MG; Dixon BE
    MMWR Morb Mortal Wkly Rep; 2022 Apr; 71(13):495-502. PubMed ID: 35358170
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Factors Associated With US Adults' Likelihood of Accepting COVID-19 Vaccination.
    Kreps S; Prasad S; Brownstein JS; Hswen Y; Garibaldi BT; Zhang B; Kriner DL
    JAMA Netw Open; 2020 Oct; 3(10):e2025594. PubMed ID: 33079199
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness of COVID-19 Vaccines in Preventing Hospitalization Among Adults Aged ≥65 Years - COVID-NET, 13 States, February-April 2021.
    Moline HL; Whitaker M; Deng L; Rhodes JC; Milucky J; Pham H; Patel K; Anglin O; Reingold A; Chai SJ; Alden NB; Kawasaki B; Meek J; Yousey-Hindes K; Anderson EJ; Farley MM; Ryan PA; Kim S; Nunez VT; Como-Sabetti K; Lynfield R; Sosin DM; McMullen C; Muse A; Barney G; Bennett NM; Bushey S; Shiltz J; Sutton M; Abdullah N; Talbot HK; Schaffner W; Chatelain R; Ortega J; Murthy BP; Zell E; Schrag SJ; Taylor C; Shang N; Verani JR; Havers FP
    MMWR Morb Mortal Wkly Rep; 2021 Aug; 70(32):1088-1093. PubMed ID: 34383730
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of Communication Strategies for Mitigating COVID-19 Vaccine-Specific Hesitancy in Canada.
    Merkley E; Loewen PJ
    JAMA Netw Open; 2021 Sep; 4(9):e2126635. PubMed ID: 34591105
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness of a Third Dose of mRNA Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance - VISION Network, 10 States, August 2021-January 2022.
    Thompson MG; Natarajan K; Irving SA; Rowley EA; Griggs EP; Gaglani M; Klein NP; Grannis SJ; DeSilva MB; Stenehjem E; Reese SE; Dickerson M; Naleway AL; Han J; Konatham D; McEvoy C; Rao S; Dixon BE; Dascomb K; Lewis N; Levy ME; Patel P; Liao IC; Kharbanda AB; Barron MA; Fadel WF; Grisel N; Goddard K; Yang DH; Wondimu MH; Murthy K; Valvi NR; Arndorfer J; Fireman B; Dunne MM; Embi P; Azziz-Baumgartner E; Zerbo O; Bozio CH; Reynolds S; Ferdinands J; Williams J; Link-Gelles R; Schrag SJ; Verani JR; Ball S; Ong TC
    MMWR Morb Mortal Wkly Rep; 2022 Jan; 71(4):139-145. PubMed ID: 35085224
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incidence of Severe COVID-19 Illness Following Vaccination and Booster With BNT162b2, mRNA-1273, and Ad26.COV2.S Vaccines.
    Kelly JD; Leonard S; Hoggatt KJ; Boscardin WJ; Lum EN; Moss-Vazquez TA; Andino R; Wong JK; Byers A; Bravata DM; Tien PC; Keyhani S
    JAMA; 2022 Oct; 328(14):1427-1437. PubMed ID: 36156706
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness of Covid-19 Vaccines over a 9-Month Period in North Carolina.
    Lin DY; Gu Y; Wheeler B; Young H; Holloway S; Sunny SK; Moore Z; Zeng D
    N Engl J Med; 2022 Mar; 386(10):933-941. PubMed ID: 35020982
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sustained Effectiveness of Pfizer-BioNTech and Moderna Vaccines Against COVID-19 Associated Hospitalizations Among Adults - United States, March-July 2021.
    Tenforde MW; Self WH; Naioti EA; Ginde AA; Douin DJ; Olson SM; Talbot HK; Casey JD; Mohr NM; Zepeski A; Gaglani M; McNeal T; Ghamande S; Shapiro NI; Gibbs KW; Files DC; Hager DN; Shehu A; Prekker ME; Erickson HL; Gong MN; Mohamed A; Henning DJ; Steingrub JS; Peltan ID; Brown SM; Martin ET; Monto AS; Khan A; Hough CL; Busse LW; Ten Lohuis CC; Duggal A; Wilson JG; Gordon AJ; Qadir N; Chang SY; Mallow C; Rivas C; Babcock HM; Kwon JH; Exline MC; Halasa N; Chappell JD; Lauring AS; Grijalva CG; Rice TW; Jones ID; Stubblefield WB; Baughman A; Womack KN; Lindsell CJ; Hart KW; Zhu Y; Stephenson M; Schrag SJ; Kobayashi M; Verani JR; Patel MM; ;
    MMWR Morb Mortal Wkly Rep; 2021 Aug; 70(34):1156-1162. PubMed ID: 34437524
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Persistence of immune responses after heterologous and homologous third COVID-19 vaccine dose schedules in the UK: eight-month analyses of the COV-BOOST trial.
    Liu X; Munro APS; Wright A; Feng S; Janani L; Aley PK; Babbage G; Baker J; Baxter D; Bawa T; Bula M; Cathie K; Chatterjee K; Dodd K; Enever Y; Fox L; Qureshi E; Goodman AL; Green CA; Haughney J; Hicks A; Jones CE; Kanji N; van der Klaauw AA; Libri V; Llewelyn MJ; Mansfield R; Maallah M; McGregor AC; Minassian AM; Moore P; Mughal M; Mujadidi YF; Belhadef HT; Holliday K; Osanlou O; Osanlou R; Owens DR; Pacurar M; Palfreeman A; Pan D; Rampling T; Regan K; Saich S; Saralaya D; Sharma S; Sheridan R; Stokes M; Thomson EC; Todd S; Twelves C; Read RC; Charlton S; Hallis B; Ramsay M; Andrews N; Lambe T; Nguyen-Van-Tam JS; Cornelius V; Snape MD; Faust SN;
    J Infect; 2023 Jul; 87(1):18-26. PubMed ID: 37085049
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of COVID-19 Incidence and Severity Among Adults Vaccinated With 2-Dose mRNA COVID-19 or Inactivated SARS-CoV-2 Vaccines With and Without Boosters in Singapore.
    Ng OT; Marimuthu K; Lim N; Lim ZQ; Thevasagayam NM; Koh V; Chiew CJ; Ma S; Koh M; Low PY; Tan SB; Ho J; Maurer-Stroh S; Lee VJM; Leo YS; Tan KB; Cook AR; Tan CC
    JAMA Netw Open; 2022 Aug; 5(8):e2228900. PubMed ID: 36018588
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants.
    Accorsi EK; Britton A; Fleming-Dutra KE; Smith ZR; Shang N; Derado G; Miller J; Schrag SJ; Verani JR
    JAMA; 2022 Feb; 327(7):639-651. PubMed ID: 35060999
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of mRNA Vaccine Boosters against SARS-CoV-2 Omicron Infection in Qatar.
    Abu-Raddad LJ; Chemaitelly H; Ayoub HH; AlMukdad S; Yassine HM; Al-Khatib HA; Smatti MK; Tang P; Hasan MR; Coyle P; Al-Kanaani Z; Al-Kuwari E; Jeremijenko A; Kaleeckal AH; Latif AN; Shaik RM; Abdul-Rahim HF; Nasrallah GK; Al-Kuwari MG; Butt AA; Al-Romaihi HE; Al-Thani MH; Al-Khal A; Bertollini R
    N Engl J Med; 2022 May; 386(19):1804-1816. PubMed ID: 35263534
    [TBL] [Abstract][Full Text] [Related]  

  • 17. From trial to practice: incidence and severity of COVID-19 vaccine side effects in a medically at-risk and vaccine-hesitant community.
    Joyce MC; Mountjoy NJ; Johnson JA; Newman JT; Bandy DL; Atalla NA; Singh A; McElroy D
    BMC Public Health; 2022 Dec; 22(1):2351. PubMed ID: 36517842
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exploring the adverse events of Oxford-AstraZeneca, Pfizer-BioNTech, Moderna, and Johnson and Johnson COVID-19 vaccination on Guillain-Barré Syndrome.
    Meo SA; Shaikh N; Abukhalaf FA; Meo AS
    Sci Rep; 2024 Aug; 14(1):18767. PubMed ID: 39138276
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative Effectiveness and Antibody Responses to Moderna and Pfizer-BioNTech COVID-19 Vaccines among Hospitalized Veterans - Five Veterans Affairs Medical Centers, United States, February 1-September 30, 2021.
    Bajema KL; Dahl RM; Evener SL; Prill MM; Rodriguez-Barradas MC; Marconi VC; Beenhouwer DO; Holodniy M; Lucero-Obusan C; Brown ST; Tremarelli M; Epperson M; Mills L; Park SH; Rivera-Dominguez G; Morones RG; Ahmadi-Izadi G; Deovic R; Mendoza C; Jeong C; Schrag SJ; Meites E; Hall AJ; Kobayashi M; McMorrow M; Verani JR; Thornburg NJ; Surie D; ; ;
    MMWR Morb Mortal Wkly Rep; 2021 Dec; 70(49):1700-1705. PubMed ID: 34882654
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.